Screener
ImmunityBio, Inc. IBRX Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Accrued preclinical and clinical trial costs | 10,258 | 5,491 |
| Accrued sales costs | 8,067 | 6,308 |
| Accrued compensation | 7,327 | 5,720 |
| Accrued bonus | 3,934 | 14,348 |
| Accrued research and development costs | 3,039 | 2,635 |
| Financing obligation | 884 | 1,751 |
| Other | 2,450 | 3,073 |
| Accrued expenses and other liabilities | $48,204 | $46,838 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s accrued expenses?
- ImmunityBio, Inc. (IBRX) reported accrued expenses of $48.2M in Q1 2026.
- How has ImmunityBio, Inc.'s accrued expenses changed year-over-year?
- ImmunityBio, Inc.'s accrued expenses increased by 72.8% year-over-year, from $27.89M to $48.2M.
- What is the long-term trend for ImmunityBio, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s accrued expenses has grown at a 5.0% compound annual growth rate (CAGR), from $36.77M to $46.84M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about ImmunityBio, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude